Overview

Phase I Study in Patients With Solid Tumours

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

This study will comprise 2 parts, a dose escalation phase and a dose expansion phase. The 2 phases are part of a single study and described by this single protocol. Patients entered into the dose escalation phase will not be entered into the expansion phase. All subjects must be suitable for treatment with either carboplatin and/or paclitaxel.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Saracatinib